一项网络meta分析显示,在治疗晚期霍奇金淋巴瘤时,采用更强烈的化疗方案可以获得明显的生存益处,但是其他专家强调这种方案的毒副作用。 这种强化化疗方案为BEACOPP(博来霉素、依托泊甙、阿霉素、环磷酰胺、长春新碱、甲苄肼和强的松),由德国开发。 这种方案在德国以外使用很少,在北美用的也不多,而一种更老的化疗方案ABVD(阿霉素、博来霉素、长春新碱和氮烯唑胺)却更受推崇。 研究表明,BEACOPP方案能够改善疾病控制,与ABDV方案相比能够延长无进展生存期(PFS)。 研究结果发表在《柳叶刀 肿瘤学》(Lancet Oncology)。 Background Several treatment strategies are available for adults with advanced-stage Hodgkin's lymphoma, but studies assessing two alternative standards of care—increased dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated), and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)—were not powered to test differences in overall survival. To guide treatment decisions in this population of patients, we did a systematic review and network meta-analysis to identify the best initial treatment strategy. Methods We searched the Cochrane Library, Medline, and conference proceedings for randomised controlled trials published between January, 1980, and